BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 27521324)

  • 21. Hematopoietic stem cell transplantation for myelodysplastic syndrome: a review.
    Parmar S; de Lima M; Deeg HJ; Champlin R
    Semin Oncol; 2011 Oct; 38(5):693-704. PubMed ID: 21943676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Life after hypomethylating agents in myelodysplastic syndrome: new strategies.
    Santini V
    Curr Opin Hematol; 2015 Mar; 22(2):155-62. PubMed ID: 25603477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?
    Robin M; Fenaux P
    Leukemia; 2020 Oct; 34(10):2552-2560. PubMed ID: 32661295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic transplantation for myelodysplastic syndrome (MDS).
    Ingram W; Lim ZY; Mufti GJ
    Blood Rev; 2007 Mar; 21(2):61-71. PubMed ID: 16759774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.
    Lindsley RC; Saber W; Mar BG; Redd R; Wang T; Haagenson MD; Grauman PV; Hu ZH; Spellman SR; Lee SJ; Verneris MR; Hsu K; Fleischhauer K; Cutler C; Antin JH; Neuberg D; Ebert BL
    N Engl J Med; 2017 Feb; 376(6):536-547. PubMed ID: 28177873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transplant for MDS: challenges and emerging strategies.
    Tamari R; Castro-Malaspina H
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):43-54. PubMed ID: 25659729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Impact of induced therapy before allogeneic hematopoietic stem-cell transplantation for higher-risk myelodysplastic syndrome: experience of single centre].
    Zhou JY; He GS; Wu DP; Sun AN; Qiu HY; Jin ZM; Tang XW; Han Y; Fu ZZ; Ma X; Miao M; Xue SL; Wang Y
    Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(40):3185-8. PubMed ID: 24405537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome.
    Shimomura Y; Hara M; Tachibana T; Ohashi K; Sakura T; Fukuda T; Nakazawa H; Iwato K; Kanda Y; Ikeda T; Eto T; Kanda J; Ichinohe T; Atsuta Y; Ishikawa T; Ishiyama K
    Br J Haematol; 2019 Jul; 186(1):86-90. PubMed ID: 30941758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haploidentical Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome.
    Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2143-2150. PubMed ID: 28865971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.
    de Witte T; Bowen D; Robin M; Malcovati L; Niederwieser D; Yakoub-Agha I; Mufti GJ; Fenaux P; Sanz G; Martino R; Alessandrino EP; Onida F; Symeonidis A; Passweg J; Kobbe G; Ganser A; Platzbecker U; Finke J; van Gelder M; van de Loosdrecht AA; Ljungman P; Stauder R; Volin L; Deeg HJ; Cutler C; Saber W; Champlin R; Giralt S; Anasetti C; Kröger N
    Blood; 2017 Mar; 129(13):1753-1762. PubMed ID: 28096091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular prognostication for transplant decision making of patients with myelodysplastic syndromes: A retrospective single-center study.
    Condorelli A; Frigeni M; Quaresmini G; Salmoiraghi S; Pavoni C; Grassi A; Raviglione M; Civini A; Putelli A; Lussana F; Finazzi MC; Algarotti A; Micò MC; Spinelli O; Rambaldi A
    Leuk Res; 2024 Jul; 142():107529. PubMed ID: 38820666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndromes.
    Platzbecker U
    Semin Hematol; 2012 Oct; 49(4):342-9. PubMed ID: 23079064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The evolution of hematopoietic SCT in myelodysplastic syndrome.
    Kindwall-Keller T; Isola LM
    Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Which Patients Should Undergo Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes, and When Should We Do It?
    Oran B
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S43-9. PubMed ID: 26297277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome.
    de Lima M; Giralt S
    Semin Hematol; 2006 Apr; 43(2):107-17. PubMed ID: 16616044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies.
    Guièze R; Damaj G; Pereira B; Robin M; Chevallier P; Michallet M; Vigouroux S; Beguin Y; Blaise D; El Cheikh J; Roos-Weil D; Thiebaut A; Rohrlich PS; Huynh A; Cornillon J; Contentin N; Suarez F; Lioure B; Mohty M; Maillard N; Clement L; François S; Guillerm G; Yakoub-Agha I
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):240-247. PubMed ID: 26256942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors.
    Sun YQ; Xu LP; Liu KY; Zhang XH; Yan CH; Jin J; Huang XJ; Wang Y
    Cancer Commun (Lond); 2021 Apr; 41(4):333-344. PubMed ID: 33566460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT.
    Cremers EM; van Biezen A; de Wreede LC; Scholten M; Vitek A; Finke J; Platzbecker U; Beelen D; Schwerdtfeger R; Volin L; Harhalakis N; Blijlevens N; Nagler A; Kröger N; de Witte T
    Ann Hematol; 2016 Dec; 95(12):1971-1978. PubMed ID: 27650829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Donor-derived myelodysplastic syndrome after allogeneic stem cell transplantation in a family with germline GATA2 mutation.
    Sakata N; Okano M; Masako R; Tanaka A; Yamashita Y; Karasuno T; Imadome KI; Okada M; Sugimoto K
    Int J Hematol; 2021 Feb; 113(2):290-296. PubMed ID: 32865708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preparing Patients With Myelodysplastic Syndrome for Transplant When Is Pre-transplant Cytoreductive Therapy Appropriate?
    Wermke M; Gloaguen S; Platzbecker U
    Curr Hematol Malig Rep; 2015 Sep; 10(3):329-33. PubMed ID: 26126601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.